Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Blood (2017) 129 (7): 846–854.

https://doi.org/10.1182/blood-2016-09-742205

Published: 2017

Journal Articles

Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis

Zoé Van de Wyngaert, MD, Greg Vanoutryve, Guillemette Fouquet, MD, Stéphanie Guidez, Charles Herbaux, MD, Helene Demarquette, MD, Loic Renaud, Louis Terriou, MD, Marie Pierre Noel, MD, Marie Odile Petillon, MD, Bénédicte Hivert, MD, Matthieu Wemeau, MD, David Launay, MDPhD, Nicolas Lamblin, MD, Eric Hachulla, MD PhD, Thierry Facon, MD, Xavier Leleu, MD

Blood (2014) 124 (21): 5664.

https://doi.org/10.1182/blood.V124.21.5664.5664

Published: 2014

Journal Articles

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Mathieu Leclerc, MD, Felipe Suarez, MD, PhD, Marie-Pierre Noël, MD, Anne Vekhoff, MD, Xavier Troussard, MD, Jean-François Claisse, MD, Catherine Thieblemont, MD, PhD, Frédéric Maloisel, MD, PhD, Yves Beguin, MD, PhD, Jérôme Tamburini, MD, PhD, Coralie Barbe, MD, Alain Delmer, MD

Blood (2013) 122 (21): 5308.

https://doi.org/10.1182/blood.V122.21.5308.5308

Published: 2013

Journal Articles

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

Francois-Xavier Mahon, MD, PhD, Franck E. Nicolini, MD, PhD, Marie-Pierre Noël, MD, Martine Escoffre, MD, Aude Charbonnier, MD, Delphine Rea, MD, PhD, Viviane Dubruille, Bruno R. Varet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, Gabriel Etienne, MD, PHD, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD

Blood (2013) 122 (21): 654.

https://doi.org/10.1182/blood.V122.21.654.654

Published: 2013

Journal Articles

The EOS ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,

Bastien Dutouquet, MD, Xavier Leleu, MD, PhD, Antoine Moraux, MD, Eileen Boyle, MD, Jordan Gauthier, MD, Houria Debarri, MD, Salomon Manier, MD, Marie Pierre Noel, MD, Thierry Facon, MD, Marie Helene Vieillard, MD, PhD, Anne Cotten, MD, Nathalie Boutry, MD, PhD

Blood (2011) 118 (21): 3921.

https://doi.org/10.1182/blood.V118.21.3921.3921

Published: 2011

Journal Articles

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

Claire Fabre, MD, Fatsiha Chermat, Laurence Legros, MD, Sophie Park, MD, François Dreyfus, MD, Françoise Isnard, MD, Florence Nowak, MD, Anne Marfaing, MD, Stéphane de Botton, MD, Marie-Pierre Noel, MD, Christophe Fruchart, MD, Thomas Prebet, MD, Norbert Vey, MD, Caroline Dartigeas, MD, Pierre Fenaux, MD PhD

Blood (2006) 108 (11): 2664.

https://doi.org/10.1182/blood.V108.11.2664.2664

Published: 2006

Journal Articles

Quantification by Magnetic Resonance Imaging (MRI) and Consequences of Post-Transfusionnal Iron Overload in Long Bone Marrow Transplant Survivors.

Christian Rose, MD, Olivier Ernst, PD, Bernard Hecquet, MD, Pascale Renom, MD, Marie Pierre Noel, MD, Ibrahim Yakoub-Agha, MD, Emmanuelle Bourgeois, MD, Nathalie Cambier, MD, Francis Bauters, MD, Jean Pierre Jouet, MD

Blood (2005) 106 (11): 1112.

https://doi.org/10.1182/blood.V106.11.1112.1112

Published: 2005

NARROW

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Safety Profile of Bortezomib Impacts Survival in Light Chain Amyloidosis

Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases

Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib

The EOS ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

Quantification by Magnetic Resonance Imaging (MRI) and Consequences of Post-Transfusionnal Iron Overload in Long Bone Marrow Transplant Survivors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only